博司捷聯合依達拉奉治療腦出血保守治療患者的療效分析

[摘要] 目的 分析單唾液酸四己糖神經節苷脂（博司捷）聯合依達拉奉治療腦出血保守治療患者的臨床療效。 方法 選取2012年1月—2014年6月該院收治的腦出血保守治療患者100例，按照隨機數字表法分為觀察組和對照組各50例。對照組在常規治療的基礎上加用神經保護劑博司捷；觀察組在對照組的基礎上加用依達拉奉；兩組的療程均為14 d。觀察兩組治療前后神經功能缺損評分（NIHSS評分）、日常生活活動能力指數（Barthel指數）和血清hs-CRP水平的變化，評價臨床療效。結果 治療前兩組的NIHSS評分、Barthel指數及血清hs-CRP水平差異無統計學意義（P>0.05）；治療后，兩組的NIHSS評分、Barthel指數及血清hs-CRP水平均較治療前明顯改善，觀察組改善情況明顯優于對照組，差異有統計學意義（P<0.05）；觀察組和對照組的臨床總有效率分別為（90% vs72%），觀察組明顯優于對照組，差異有統計學意義（χ2=2.846，P<0.05）。結論 博司捷聯合依達拉奉能明顯減輕腦出血保守治療患者炎性反應，改善神經功能和日常生活活動能力，療效顯著，值得臨床推廣應用。

[關鍵詞] 腦出血保守治療患者；神經保護治療；單唾液酸四己糖神經節苷脂；依達拉奉

[中圖分類號] R749.1 [文獻標識碼] A [文章編號] 1674-0742（2015）02（a）-0102-03

The clinical curative effect observation of GM-1 joint edaravone for the treatment of Conservative treatment of patients with cerebral hemorrhage

YANG Rongguo

PLA eighty-eighth hospital， Department of pharmacy Shandong Tai'an 271000，China

[Abstract] Objective To observe the clinical curative effect of monosialoteterahexosyl ganglioside joint edaravone for the treatment of Conservative treatment of patients with cerebral hemorrhage. Methods Selected 100 cases of patients in our hospital from January 2012- June 2014， divided into observation group and control group（n=50 ）， according to random number table method.The control group given nerve protectant GM - 1 treatment； The observation group given GM-1 joint edaravone treatment ；the course for 14d. Observe the nerve function defect score （NIHSS score）， daily life activities ability index （Barthel index） and serum hs-CRP level of two groups before and after the treatment ， evaluate the clinical efficacy. Results The NIHSS score， Barthel index and serum hs - CRP level of the two groups before treatment had no statistical significance difference （P > 0.05）；After treatment， the NIHSS score， Barthel index and serum hs - CRP level of the two groups were obviously improved， the observation group was obviously superior to the control group， the difference has statistically significant （P < 0.05）； The clinical total effective rate of the observation group and the control group respectively was （90% vs72%）， the observation group was better than the control group， the difference has statistical significance （χ2=2.846， P < 0.05）. Conclusion GM - 1 joint edaravone can obviously alleviate the inflammatory reaction，improve neural function and life quality of the patients the curative effect is distinct， worthy of clinical popularization and application.

[Key words] Conservative treatment of patients with cerebral hemorrhage；Nerve protection treatment； Monosialoteterahexosylganglioside； Edaravone

腦出血保守治療患者是臨床常見的神經科疾病，具有發病急、進展快、致殘率高、病死率高、復發率高、并發癥多等特點，嚴重影響人們的身心健康和生命安全，因此關于腦出血保守治療患者的治療具有重要的臨床意義[1]。腦神經保護治療是腦出血保守治療患者的重要治療手段之一。自“神經保護療法”這一概念被提出依賴，許多的研究者對腦出血保守治療患者神經保護劑的應用進行了大量的研究[2]。……